Powered by

-Soligenix Announces US Patent Issuance for Use of Dusquetide in Oral Mucositis

Princeton, NJ - Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the United States (US) Patent Office has granted the patent entitled 'Novel Peptides and Analogs for Use in the Treatment of Oral Mucositis.'

The newly issued patent claims therapeutic use of dusquetide (active ingredient in SGX942) and related in

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 5 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox